Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings.
Vol 23, No 16S (June 1 Supplement), 2005: 3515
© 2005 American Society of Clinical Oncology

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hochster, H. S. Articles by Emanuel, D. Search for Related Content PubMed Articles by Hochster, H. S. Articles by Emanuel, D.

Abstract

Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 Studies

NYU Sch of Medicine, New York, NY; Sanofi Aventis, New York, NY; Florida Cancer Specialists, Fort Myers, FL; Univ of Pittsburgh Cancer Ctr, Pittsburgh, PA; Sarah Cannon Cancer Ctr, Nashville, TN; sanofi-aventis, New York, NY; Genentech, Inc, South San Francisco, CA

3515

Background: Bevacizumab (Bev) added to IFL combination chemotherapy improves survival in mCRC. This randomized study assesses the safety & tolerability of each of three Oxaliplatin plus fluoropyrimidine regimens (bolus (b), infusional or oral fluoropyrimidine) alone in TREE1, and with Bev in TREE2. Methods: Eligibility: age 18; measurable untreated mCRC; PS 1. Primary endpoint: Grade 3/4 toxicities in the 1^st 12 weeks (wk) of Rx; secondary endpoints: TTP, OS. Oxali-FU (in mg/m²) regimens consisted of: FOLFOX = O 85, leucovorin (LV) 350mg, 5FU bolus 400 & 2400 CIV x 46 hrs q 2 wk; bFOL = O 85 days (d) 1&15, LV 20 & bolus 5FU 500 d 1,8,15 q 4 wk; CapOx = O130 d 1, Capecitabine 1000 bid (850 for TREE2) for 14 d q 3 wk; Bev was added to each regimen (5 mg/kg q 2 wk or 7.5 mg/kg q 3 wk) in TREE2. Results: 147 pts were entered in TREE1 and 213 pts in TREE2. Selected gr 3/4 toxicity during 1^st 12 wks of treatment is shown in table. Addition of B in TREE 2 caused increased gr 3/4 hypertension, impaired wound healing (5%) and bowel perforation (3%) in each arm. Confirmed ITT ORR (TREE1/2 respectively) = FOLFOX 39%/49%, bFOL 20%/34%, CapOx 29%/43% Conclusions: Grade 3–4 toxicity with first line Bev plus Oxaliplatin-based chemotherapy is acceptable and less than reported for IFL. All regimens of fluoropyrimidine administration are active but FOLFOX has best balance of response and toxicity. CapOX tolerance improved using reduced Cap 850 mg/m2 bid. Bev significantly improved RR (p=0.011, pooled logistic regression analysis) when added to Oxaliplatin-fluoropyrimidine chemotherapy. Additional efficacy data (TTP; OS) is not mature at time of abstract, but will be presented.

View larger version (23K): [in this window] [in a new window]

Abstract presentation from the 2005 ASCO Annual Meeting